NCT02645981View on ClinicalTrials.gov

Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

668

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

November 27, 2019

Study Completion Date

December 17, 2019

Conditions
HCC
Interventions
DRUG

Donafenib

Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects

DRUG

Sorafenib

Control

Trial Locations (2)

610042

West China Hospital Sichuan University, Chengdu

025

The PLA 81 Hospital, Nanjing

All Listed Sponsors
collaborator

Tigermed Consulting Co., Ltd

INDUSTRY

lead

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

INDUSTRY

NCT02645981 - Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter